FDA Approves Palbociclib for HR-Positive HER2-Positive Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved palbociclib (Ibrance, Pfizer) as the first and only cyclin-dependent kinase 4/6 inhibitor for adults with HR-positive, HER2-positive metastatic breast cancer, according to a Pfizer press release. This approval marks a significant advancement in treating a subset of patients who often face resistance to dual anti-HER2 and endocrine therapies, the agency said.

Key Trial Results Show Improved Progression-Free Survival

The decision followed data from the phase 3 PANTINA trial, which enrolled 518 patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer. Participants who received palbociclib in combination with trastuzumab (Herceptin), with or without pertuzumab (Perjeta), and endocrine therapy experienced a 24% reduction in progression-free survival (PFS) compared to those receiving trastuzumab-based therapy alone, according to the trial’s findings.

“Resistance to dual anti-HER2 and endocrine therapy remains a central clinical challenge for patients with HR-positive, HER2-positive metastatic breast cancer,” said Dr. Otto Metzger, a medical oncologist at Dana-Farber Cancer Institute, in a Pfizer statement. “The addition of Ibrance in the maintenance phase can meaningfully extend the time patients go without their disease progressing.”

How Palbociclib Works in Combination Therapy

Palbociclib is recommended at a dose of 125 mg orally once daily for 21 days, followed by a 7-day break, in each 28-day cycle. The drug works by inhibiting CDK4/6, a pathway involved in cancer cell proliferation, according to the National Cancer Institute. In the PANTINA trial, the safety profile aligned with previously reported adverse events, including hematologic toxicities, diarrhea, and fatigue.

What This Means for Patients and Oncologists

The approval provides oncologists with a new evidence-based option to optimize maintenance therapy for patients with HR-positive, HER2-positive disease, as noted by Metzger. While overall survival (OS) data from the trial were not yet mature at the time of analysis, the PFS benefit offers a tangible improvement in disease control, according to the FDA.

Patients eligible for the treatment must have achieved no evidence of disease progression after induction therapy with a taxane and trastuzumab, with or without pertuzumab, as per trial criteria.

Next Steps for Research and Clinical Practice

Experts emphasize the need for ongoing monitoring of long-term outcomes, including OS and potential resistance mechanisms. The PANTINA trial’s results highlight the importance of integrating CDK4/6 inhibitors into the treatment paradigm for HER2-positive breast cancer, a focus area for future studies, according to the American Society of Clinical Oncology (ASCO).